Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31536856 | 0.90 | PSMB8 (0.42) | PSMB8PSMB5PSMB10PIM1MAOA | |
| SCHEMBL26507916 | 0.90 | MAOA (0.38) | PSMB8PSMB5PSMB10PIM1MAOA | |
| SCHEMBL29395157 | 0.84 | MEN1 (0.53) | PSMB5PIM1MAOAMAPTMEN1 | |
| SCHEMBL23198970 | 0.80 | MAPT (0.47) | PIM1MAOAMAPTMEN1KMT2A | |
| Austrocortirubin SCHEMBL23199031 | 0.77 | LCK (0.56) | PIM1MAOAMAPTMEN1KMT2A | |
| Austrocortirubin SCHEMBL29357393 | 0.77 | LCK (0.56) | PIM1MAOAMAPTMEN1KMT2A | |
| SCHEMBL29709363 | 0.75 | PIM1 (0.69) | PSMB5PIM1MAOAMAPTMEN1 | |
| Scorpinone SCHEMBL28573056 | 0.73 | ALDH1A1 (0.64) | PSMB8PSMB5PSMB10MAOAMAPT | |
| SCHEMBL5820346 | 0.70 | MEN1 (0.47) | PIM1MAOAMAPTMEN1KMT2A | |
| SCHEMBL29359878 | 0.70 | PIM1 (0.44) | PIM1MAPTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1808169-B1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTEOTECH INC (US) | 2012-05-30 | — | — | EP | claimed |
| JP-4370072-B2 | — | — | 2009-11-25 | — | — | JP | claimed |
| US-20070191330-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTEOTECH, INC. | 2007-08-16 | — | — | US | claimed |
| EP-1808169-A2 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | Proteotech Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| US-20040152760-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2004-08-05 | — | — | US | claimed |
| JP-2003532634-A | — | — | 2003-11-05 | — | — | JP | claimed |
| EP-1244435-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES | Proteotech Inc. (US) | 2002-10-02 | — | — | EP | claimed |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001049281-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES | PROTEOTECH, INC. (US) | 2001-07-12 | — | — | WO | claimed |
| EP-4499807-B1 | ISOLATED FUSARIUM SOLANI IIA AND ITS USE FOR DYEING SUBSTRATES | VTL GMBH (AT) | 2026-05-06 | — | — | EP | disclosed |
| US-20250360073-A1 | SOLUBILIZING PIGMENTS EXTRACTED FROM FUNGI FOR APPLICATIONS SUCH AS COSMETIC PRODUCTS | ADLER JESSE (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250297108-A1 | ISOLATED FUSARIUM SOLANI IIa AND ITS USE FOR DYEING SUBSTRATES | VTL GMBH (AT) | 2025-09-25 | — | — | US | disclosed |
| WO-2025059358-A1 | FUNGAL STRAINS HAVING REDUCED OR ELIMINATED MYCOTOXIN, ETHANOL, AND/OR PIGMENT PRODUCTION CAPACITY | THE FYNDER GROUP, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-109879885-B | Novel compound and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2020-06-19 | — | — | CN | disclosed |
| WO-2002100478-A9 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002100478-A2 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1244435-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES | Proteotech Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001049281-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES | PROTEOTECH, INC. (US) | 2001-07-12 | — | — | WO | disclosed |
| EP-0234431-A2 | 5-Hydroxydihydrofusarubin, a process for its preparation and its use for the preparation of a medicament | HOECHST JAPAN LIMITED (JP) | 1987-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191330-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | PSMB8 1072/4885PSMB5 883/4885PSMB10 618/4885 |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | PSMB8 1155/4885PSMB5 921/4885PSMB10 649/4885 |
| US-20040152760-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | PSMB8 1155/4885PSMB5 921/4885PSMB10 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.